Overview

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
A prospective, randomized, double-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to sham
Phase:
Phase 2
Details
Lead Sponsor:
EyePoint Pharmaceuticals, Inc.
Treatments:
Aflibercept